Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both...
Jun 27, 2025, 9:15 AM EDT - 10 days ago
May 1, 2025, 5:00 PM EDT - 2 months ago
Dec 20, 2024, 9:00 AM EST - 7 months ago
Dec 18, 2024, 8:30 AM EST - 7 months ago
Nov 21, 2024, 9:49 AM EST - 8 months ago
Oct 29, 2024, 8:30 AM EDT - 8 months ago
Oct 24, 2024, 8:45 AM EDT - 9 months ago
Sep 16, 2024, 8:35 AM EDT - 10 months ago
Aug 7, 2024, 8:45 AM EDT - 11 months ago
Jul 15, 2024, 9:00 AM EDT - 1 year ago
May 13, 2024, 9:00 AM EDT - 1 year ago
Apr 9, 2024, 8:30 AM EDT - 1 year ago
Mar 21, 2024, 8:30 AM EDT - 1 year ago
Mar 18, 2024, 10:00 AM EDT - 1 year ago
Mar 11, 2024, 9:00 AM EDT - 1 year ago
Feb 27, 2024, 8:00 AM EST - 1 year ago
Feb 21, 2024, 4:47 PM EST - 1 year ago
Feb 17, 2024, 7:45 AM EST - 1 year ago
AMDI MTRS RCAT SSII UMAC WETH
Feb 16, 2024, 8:00 AM EST - 1 year ago
Oct 19, 2023, 5:31 PM EDT - 1 year ago
Feb 2, 2023, 1:35 PM EST - 2 years ago